Skip to main content

Table 1 Characteristics of included trials on XST for ACI

From: Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis

Study ID

Sex (M/F)

Age (a)

Course of disease (h)

N (E/C)

Intervention

Duration (days)

Outcomes

ADR/ADE

Experimental

Control

Li 1999 [15]

29/33

62.9 ± 7.1 (57 ~ 71)

≤48

31/31

XST 400 mg + WM

WM (Defibrase et al.)

14

Total effective rate, changes in cerebral blood flow and hemorheology

Unclear

Zhang 2002 [16]

52/48

53.0 (37 ~ 70)

≤72

60/40

Luotai 400 mg + WM

Xiaoshuanling + WM

14

Total effective rate

Unclear

Yuan 2003 [17]

37/25

42 ~ 79

≤72

32/30

XST 20 ml + WM

WM (Piracetam et al.)

15

Total effective rate, changes in hemorheology

Unclear

Li 2003 [18]

69/27

55.8 (42 ~ 71)

≤72

48/48

XST 400 mg

WM (Dextran 40 + citicoline)

15

Total effective rate

Unclear

Li 2005 [19]

-

48 ~ 73

≤72

80/76

XST 200 mg + WM

WM

20

Total effective rate

E 3

He 2006 [20]

48/32

59.3 ± 12.1 (46 ~ 80)

≤72

40/40

XST 10 ml + WM

Dextran 40 + WM

14

Total effective rate, neurological deficit score

None

Wang 2006 [21]

34/21

63.8 (39 ~ 79)

≤24

36/19

XST 600 mg + WM

Venoruton + WM

21

Total effective rate

None

Yuan 2006 [22]

64/31

63.0 ± 10.4 (46 ~ 74)

≤24

49/46

XST 250 ~ 500 mg + WM

WM (Defibrase et al.)

15

Total effective rate

E 3

C 7

Zhao 2006 [23]

43/38

60.9 ± 8.1 (45 ~ 70)

≤72

40/41

XST 10 ml + WM

WM (Sodium ozagrel + Defibrase et al.)

14

Total effective rate, changes in hemorheology

Unclear

Li 2007 [24]

54/36

59.5 ± 13.2 (48 ~ 79)

≤48

45/45

XST 10 ml + WM

Dextran 40 + WM

15

Total effective rate

None

Wang 2007A [25]

50/26

63.6 (39 ~ 82)

≤24

50/26

XST 600 mg + WM

Venoruton + WM

21

Total effective rate

None

Wang 2007B [26]

-

69.4 (43 ~ 80)

≤72

30/30

XST 20 ml + WM

WM (Venoruton et al.)

14

Total effective rate

None

Rong 2008 [27]

50/46

59.1 ± 8.4 (39 ~ 77)

≤72

51/45

XST 400 mg + WM

Venoruton + WM

14

Total effective rate, neurological deficit score, Modified Barthel Index, changes in hemorheology

None

Zhang 2008 [28]

70/50

56 ± 11 (48 ~ 78)

≤48

65/65

XST 200 ~ 400 mg + WM

WM

15

Total effective rate, changes in hemorheology

Unclear

Zi 2008 [29]

49/33

59.5 ± 13.2 (48 ~ 79)

≤48

41/41

XST 10 ml + WM

Dextran 40 + WM

15

Total effective rate, neurological deficit score

None

Duan 2009 [30]

35/34

64.5 ± 8.2 (33 ~ 75)

≤48

36/33

XST 500 mg + WM

WM

14

Total effective rate

None

Ma 2009 [31]

117/83

65.1 ± 7.0 (45 ~ 85)

≤72

100/100

XST 400 mg + WM

Venoruton + WM

15

Total effective rate, neurological deficit score, changes in hemorheology, glycemia and lipidemia

E 9

C 10

Cai 2011 [32]

42/18

64.2 (47 ~ 86)

≤48

30/30

XST 400 mg + WM

WM (Buflomedil hydrochloride + Low molecular heparin)

14

Total effective rate, neurological deficit score

E 2

C 1

Fu 2011 [33]

62/58

55.4 ± 5.1

≤48

64/58

XST 400 mg + WM

WM (Sodium ozagrel et al.)

14

Total effective rate, neurological deficit score

None

He 2011 [34]

57/65

59 ~ 78

≤72

62/60

XST 200 mg + WM

WM (Citicoline, Aspirin)

14

Total effective rate, neurological deficit score

None

Wang 2011 [35]

45/37

55.87 ± 5.23 (42 ~ 76)

≤19

41/41

XST 400 mg + WM

WM

21

Total effective rate, Hs-CRP

Unclear

Yang 2012 [36]

33/27

57 ± 4 (47 ~ 68)

≤48

30/30

XST 400 mg + WM

WM (Sodium ozagrel et al.)

14

Total effective rate

C 2

Song 2013 [37]

117/43

62.1

≤24

80/80

XST 400 mg + WM

WM

15

Total effective rate

Unclear

  1. NOTE: M: Males; F: Females; E: Experimental group; C: Control group; ADR: Adverse drug reactions; ADE: Adverse drug events; XST: Xuesaitong Injection; WM: Conventional therapy with western medicines, such as Dextran-40, Mannitol, Aspirin, Citicoline, Venoruton, Defibrase, Sodium ozagrel, et al.